Geode Capital Management LLC Lowers Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Geode Capital Management LLC decreased its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 1.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,846,675 shares of the company’s stock after selling 70,819 shares during the period. Geode Capital Management LLC owned 0.55% of ImmunityBio worth $14,312,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. State Street Corp lifted its holdings in ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after buying an additional 790,408 shares during the period. Barclays PLC lifted its holdings in ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after buying an additional 202,248 shares during the period. HighTower Advisors LLC purchased a new stake in ImmunityBio during the third quarter worth $136,000. Bank of New York Mellon Corp lifted its holdings in ImmunityBio by 37.9% during the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock worth $3,928,000 after buying an additional 170,742 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after buying an additional 4,545 shares during the period. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IBRX shares. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Friday, December 20th.

ImmunityBio Trading Down 3.6 %

Shares of IBRX stock opened at $2.68 on Tuesday. The business’s fifty day simple moving average is $4.40 and its 200-day simple moving average is $4.60. The company has a market cap of $1.87 billion, a PE ratio of -2.91 and a beta of 0.86. ImmunityBio, Inc. has a 12-month low of $2.50 and a 12-month high of $10.53.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.